Anand Kumar/AI-Generated Image
Summary: Two hospital chains, near-identical profits. One runs almost twice as many beds. That gap has to show up somewhere, and it does, just not where you would expect. What it says about where each one's next phase of growth must come from is the part worth sitting with.
Fortis Healthcare and Aster DM Quality Care generate similar EBITDA, trade at broadly comparable market caps and both expect hospital demand and higher-value treatments to drive growth for years, but on very different paths.
Fortis is entering its next phase with a relatively mature network: most important hospitals already generate healthy margins, several run at high utilisation, and capacity is being added mainly around established clusters. Aster has taken the opposite route: its merger with Quality Care created a network of more than 10,000 operational beds across Aster, CARE Hospitals, KIMSHEALTH and Evercare, far larger than Fortis by bed count but earlier in maturity, and Aster plans to add more than 4,000 more beds, over twice Fortis's planned addition.
Similar economics, different starting points
Hospitals are inherently operating-leverage businesses: much of the cost base, doctors, equipment, operating theatres, administration, is committed whether occupancy is 50 or 75 per cent. As utilisation improves and hospitals handle more complex procedures, additional revenue generates disproportionately higher profits.
Fortis's hospital EBITDA margin has increased from around 16 per cent in FY22 to more than 22 per cent in FY26. Legacy Aster has undergone a similar improvement, while Quality Care entered the merger with an EBITDA margin of around 23 per cent.
But their assets are at different stages.
Fortis's stronger hospitals are already well established. Its 14 hospitals earning more than 20 per cent EBITDA margins generated around 70 per cent of hospital revenue in Q1 FY27 and were operating at roughly 74 per cent occupancy.
Aster's mature hospitals are also highly profitable: the mature cohort of the merged network contributes roughly 73 per cent of revenue and operates at EBITDA margins close to 30 per cent. The drag on group margins comes more from focus and emerging hospitals that haven't reached similar economics yet.
Fortis is trying to replicate what already works
Fortis plans to add roughly 1,700-1,800 beds, much of it around existing hospitals and clusters where demand is already visible, usually less risky than entering a new market.
Fortis's recent growth also suggests volumes are becoming more important: in Q1 FY27, hospital revenue grew around 19 per cent even though revenue per occupied bed increased only modestly, most of it coming from a rise in occupied beds.
This is important because Fortis cannot rely indefinitely on the margin expansion and strong ARPOB growth that supported the previous phase.
Aster starts with much more installed capacity
Following the Quality Care merger, Aster has more than 10,500 operational beds against Fortis's roughly 6,000-plus, yet the two produce similar quarterly revenue and EBITDA. Part of the explanation is monetisation: Fortis's FY26 ARPOB works out to roughly Rs 69,000 per occupied bed per day, against around Rs 50,000 for the combined Aster business.
Geography explains some of the difference too: Fortis has greater exposure to expensive metropolitan markets, while Aster and Quality Care lean more on South India and Tier-II and Tier-III markets.
Even moderate improvements in Aster's case mix, pricing and utilisation across a much larger installed network can translate into meaningful absolute revenue growth.
This is where Aster's existing capacity becomes interesting. Its blended occupancy remains below Fortis's, but the mature hospitals are already profitable; the lower group number partly reflects younger, ramping facilities. That means some of Aster's future earnings growth can come from existing beds moving towards mature economics, not solely new construction.
Yet Aster is expanding further
Aster plans to increase capacity by more than 4,000 beds over the next few years, taking its network towards 15,000 beds.
There is a reasonable explanation: hospital capacity is local, spare capacity in Kerala does not solve overcrowding in Hyderabad, and much of the expansion is brownfield around established hospitals. Still, bed additions are not themselves value creation. A new hospital initially brings depreciation, staff costs and operating expenses before mature earnings arrive.
The merger gives Aster another lever
Quality Care makes the story more complicated but also more attractive.
This was not a merger between a strong company and a weak one: in FY26, legacy Aster and Quality Care generated almost identical revenue, and Quality Care actually had the higher EBITDA margin, so the enlarged company begins with two healthy platforms. Management also expects merger synergies to eventually add around Rs 150-200 crore to EBITDA, credible given the network's scale, though not to be assumed until it shows up in reported numbers.
The trade-off is complexity: Fortis predominantly operates one hospital brand alongside Agilus Diagnostics, while Aster must coordinate four established brands across regions, preserving the local reputation and doctor relationships that make them valuable. Its potential upside is larger, but so is what management must execute simultaneously.
Valuation does not settle the argument yet
Headline P/E makes Aster appear dramatically more expensive than Fortis, but that comparison is misleading: its merger became effective only in July 2026, so today's share count reflects the enlarged company while historical statutory earnings still largely represent legacy Aster.
On a normalised current run-rate basis, the picture looks very different. Fortis appears to trade at around 65 times normalised annualised earnings. Using legacy Aster's normalised Q1 profit and Quality Care's historical PAT conversion suggests Aster is probably also around 63-65 times. Likewise, both trade around 30-31 times annualised Q1 EBITDA.
So which one looks better?
Fortis offers the easier path to forecast. Its mature hospitals already show strong utilisation and margins; expansion is relatively measured, much of it surrounds proven assets, and its organisational structure is simpler.
Aster offers more moving parts, but also more avenues for growth: a larger existing network, more facilities progressing towards mature economics, potential merger synergies, and a capacity programme more than twice Fortis's size. At roughly similar valuations, that makes Aster's growth runway difficult to ignore.
But the extra beds only create value if they eventually earn good returns. That leaves the most important distinction between the two. Fortis needs to show that it can continue deploying capital around an already-successful hospital network without paying too much for growth. Aster needs to show that it can turn a much larger and faster-growing pool of capacity into mature, high-return hospitals.
Also read: VIP was winning. Then Safari changed the game
Ask Value Research 
New episodes every Friday 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
